What Analysts Think of Eli Lilly Stock Ahead of Earnings | Global News Avenue

Eli Lilly (Liberal) It is planned to report the income of the fourth quarter before the bells on Thursday. Analysts predict that because the company’s weight loss pills are no longer lacking, the sales and profits in the first quarter will increase.

Analysts watched the manufacturer of diet pills Zepbound With Mounjaro, there are 10 of the 11 analysts of the company, and the visible Alpha rating Eli Lilly Stock is used as “buy”, one and and and with “Keep” ratingEssence The only holding rating is also the only analyst at the current level of stock targets lower than the current level. The average price target is nearly 986 US dollars, which is about 21 % higher than its daily level on Monday.

Eli Lilly is expected to report revenue of US $ 13.63 billion, an increase of more than 45 % year -on -year, because weight loss pills have increased Eli Lilly’s revenue in the past few quarters. net income According to the estimate of Visible Alpha compilation, from the same period last year, it is expected to reach $ 4.58 billion or $ 5.06 per share from the same period last year.

Sales forecast for revenue follow

Yililai’s income is that after the pharmaceutical dealer has reduced the expectations of it again Sales in the fourth quarter of last month and Results in the third quarter Disappointed in October.

The company said in January that the growth rate of Mounjaro and Zepbough was slower than expected in the latest quarter. It is expected that in the fourth quarter and annual revenue of US $ 13.5 billion and US $ 45 billion, respectively. CEO David Ricks also said that the company predicts that compared with the period in 2024, the “dosage dose” of “weight loss drugs” in the first half of this year has increased by 60 %.

Eli Lilly and weight loss drug manufacturers to competitors Novo Nordisk (Non -governmental organization) Make ozempic and wegovy constantly watch the needs More than their supply Weight loss pill. Lilly drug Delete The shortage list of the Food and Drug Administration (FDA) At the end of last yearBoth companies have Speed ​​billions of dollars Improve its production capacity.

Eli Lilly’s stock rose on Monday, but the level of record last year declined, although it has increased by more than 20 % in the past 12 months.